Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab subcutaneous versus intravenous administration in first-line low-tumor-burden follicular lymphoma
2014-000128-22Phase 3Completed
- Sponsor
- LYSARC
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) and mature B-cell lymphoma (2 arms), sponsored by LYSARC. Primary endpoint: Progression-free survival. Started Jan 2015; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2014-000128-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000128-22.